FSHD Clinical Trial
— MOVE FSHDOfficial title:
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) will have approximately 450 FSHD participants followed for a minimum of 3 years. A subset of MOVE FSHD participants, approximately 200, will participate in the MOVE+ sub-study which includes whole body MRI and muscle biopsy.
Status | Recruiting |
Enrollment | 450 |
Est. completion date | January 2027 |
Est. primary completion date | December 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Genetically confirmed FSHD (types 1 or 2) or clinical diagnosis of FSHD with characteristic findings on exam and an affected parent or offspring. Exclusion Criteria: - Unwilling or unable to provide informed consent. - Any other medical condition which in the opinion of the investigator would interfere with study participation. |
Country | Name | City | State |
---|---|---|---|
Canada | University of Calgary | Calgary | Alberta |
Canada | University of McGill | Montreal | Quebec |
Canada | Ottawa Hospital Research Institute | Ottawa | Ontario |
United Kingdom | Sheffield Teaching Hospital | Sheffield | South Yorkshire |
United States | University of Colorado Anschutz Medical Campus | Aurora | Colorado |
United States | Kennedy Krieger Institute | Baltimore | Maryland |
United States | Nationwide Children's Hospital | Columbus | Ohio |
United States | The Ohio State University Medical Center | Columbus | Ohio |
United States | Univeristy of Texas Southwestern Medical Center | Dallas | Texas |
United States | Univeristy of Florida Gainesville | Gainesville | Florida |
United States | University of Iowa | Iowa City | Iowa |
United States | Univeristy of Kansas Medical Center | Kansas City | Kansas |
United States | David Geffen School of Medicine at UCLA | Los Angeles | California |
United States | Virginia Commonwealth University | Richmond | Virginia |
United States | University of Rochester Medical Center | Rochester | New York |
United States | University of Utah | Salt Lake City | Utah |
United States | University of Washington Medical Center | Seattle | Washington |
United States | Neuromuscular Disorders Program at Stanford University School of Medicine | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
University of Kansas Medical Center | AMRA Medical, Avidity Biosciences, Inc., Dyne Therapeutics, Friends Research Institute, Inc., FSHD Canada, FSHD Society, Inc., Hoffmann-La Roche, Seattle Children's Hospital, University of Nevada, Reno, University of Rochester |
United States, Canada, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Biospecimen Retention: Samples with DNA, RNA, plasma, and serum | Optional sub-study collecting DNA, RNA, plasma, and serum for biobanking. | Baseline - 3 years | |
Other | Remote Assessment Pilot | A sub-group of approximately 20 participants will perform remote assessments in the home. The remote assessments are meant to capture the assessments that occur during a routine in-person visit, and will overlap functional categories, to include reaching and lifting objects, core functional measures, measures of gait and balance, and midarm and hand tasks. Measures of respiratory (FVC, FEV1, PCF, SNIP), bulbar function, and handgrip strength will also be included. Functional measures will be modified to allow for independent and/or via two-way video performance. | Baseline - 3 years | |
Other | MRI | Whole body MRI will be performed for a sub-group of approximately 200 participants. MRI is recognized as a gold standard for body composition analysis, enabling a more complete description of a person's body composition profile from a single examination.In addition, we will include analysis to help make needle biopsy based on STIR and quantitative fat fraction more efficient with higher yield using standard fiducial markings and body landmarks. | Baseline - 12-Month | |
Other | Muscle Biopsy | Muscle biopsy will be performed for a sub-group of approximately 200 participants. Muscle biopsies will be performed at the baseline visit and for a subset of 20 participants at 4 months. We will use MRI analysis to help inform which lower extremity muscle will be chosen for biopsy. Muscle samples will be used to recapitulate RNA sequencing to confirm prior DUX4 target selection. In addition, other early or late genes of interest may be included which are FSHD-related but not specific to DUX4. We will also select 4 control genes for quality assurance, 2 to confirm muscle tissue, and 2 to rule out high fat content. | Baseline - 4-Month | |
Other | Reachable and Functional Workspace | Reachable and Functional Workspace will be performed for a sub-group of approximately 200 participants. Participants are seated in front of a stereo-camera and perform a standardized upper extremity movement protocol under the supervision of a study clinical evaluator. Five-hundred-gram wrist weights will be added. The standardized simple set of movements consist of lifting the arm from the resting position to above the head while keeping the elbow extended, performing the same movement in vertical planes at around 0, 45, 90, 135 degrees. The second set of movements consists of horizontal sweeps at the level of the umbilicus and shoulder. Each set of movements is repeated three times for left and right arm. | Baseline - 24-Months | |
Other | Syde Wearable Device | The purpose of the wearable device is to accurately measure upper and lower limb movement during normal daily living. In FSHD, muscles are affected asymmetrically, therefore, measurements with the wearable device will be taken from the upper and lower limbs bilaterally. | Baseline - 24-Months | |
Other | Motor Function Measure 32 (MFM32) | 32-item Motor Function Measure (MFM32) is a clinician-reported outcome measure used to assess the functional abilities of individuals with neuromuscular diseases. | Baseline - 24-Months | |
Other | FSHD COM Peds | We will collect the FSH-Composite outcome measure for children and adolescents. As with the FSHD-COM, the body regions assessed match areas of importance identified by patients and include leg function; shoulder and arm function; trunk function, hand function; and functional balance. The FSHD-COM Peds was modified by adding lighter weights to the shoulder abduction and flexion and elbow flexion items to accommodate motor development and lower strength levels seen in children. Most of the items are scored on a 5-point ordinal scale (0 = normal/not affected and 4= being severely affected or unable to complete the item) with the exception of the shoulder abduction/flexion and elbow flexion items which have been expanded and are scored on a 7-point scale using the additional weight categories. Thus, the total score for the FSHD-COM Peds is 84 (compared to 72 for the FSHD-COM). | Baseline - 24-Months | |
Primary | 10m walk/run | The 10-meter walk/run (previously the 30 foot go) or gait speed task will be performed during study visits. This task tests a range of different abilities, from power, to endurance, and balance. Also, the 10 meter walk/run is a predictor of loss of ambulation in Duchenne Muscular Dystrophy. | Baseline - 3 years | |
Primary | Shoulder and Arm Range of Motion | Range of motion tasks mimicking lifting or reaching up will be performed. | Baseline - 3 years | |
Primary | Shoulder and Arm Function | Participants will be timed on stacking cans. | Baseline - 3 years | |
Primary | Spirometry (FVC, FEV1, PCF) | Investigators will obtain forced vital capacity and forced expiratory volume in 1 second, both standardized outcomes used commonly in clinic and clinical trials. Also, for sites who routinely collect Peak Cough Flow this will also be obtained. | Baseline - 3 years | |
Secondary | Trunk Function | There are no specific functional tasks designed to measure trunk function in FSHD so Investigators have chosen a practical task that will reflect changes in core truncal muscle groups. The ability to sit up and the timed supine to sitting test reflects core muscle strength and coordination. | Baseline - 3 years | |
Secondary | Hand Function | Hand function is captured by examining hand grip strength. | Baseline - 3 years | |
Secondary | Timed Up and Go (TUG) | Balance and mobility are assessed by using the Timed Up and Go (TUG), a standard outcome measure for the elderly that is also increasingly being used in neuromuscular disorders. Participants are asked to rise from a chair, walk 3 meters, turn 180 degrees and return to a seated position in the chair. | Baseline - 3 years | |
Secondary | Saliva Methylation | Investigators will isolate DNA from blood cells in saliva - and will determine the methylation levels in the 4q region on chromosome 4 using this new technique. Investigators will compare methylation levels between participants and compare to other clinical information collected in this study. | Baseline - 3 years | |
Secondary | FSHD Clinical Severity Scores | A limited physical exam and strength testing will be used to derive two FSHD clinical severity scores. These severity scores both rank weakness in the face, shoulders, arms, distal, and proximal lower extremities on either a 10 or 15 point scale. The higher the severity score the more affected the individual. | Baseline - 3 years | |
Secondary | Patient-Reported Outcomes Measurement Information System-57 (PROMIS57) | The PROMIS57 is an instrument developed by the NIH which generates scores for physical function, and the impact of physical limitations on daily life. 57 questions are summed into a total score, which is transformed into a normalized t-score with 50 representing normal, and lower scores representing increasing disability. | Baseline - 3 years | |
Secondary | The Upper Extremity Functional Index | This index measures upper extremity dysfunction. 20 questions are combined into a total score, the score is transformed into a normalized score with 80 representing normal, and lower scores representing increasing disability. | Baseline - 3 years | |
Secondary | Exercise and Pain Assessment | An exercise and pain assessment questionnaire was comprised specifically for this study and will be completed at every visit. | Baseline - 3 years | |
Secondary | The Facial Disability Index (FDI) | The FDI is a short 5 item questionnaire. The five questions are summed into total score which transformed onto a percentage scale, with 100 representing normal, and lower scores representing increasing disability. | Baseline - 3 years | |
Secondary | FSHD Rasch-built overall disability scales (FSHD-RODS) | The FSHD-RODS is a questionnaire about the relationship between daily activities and health. 32 questions are are constructed using a modern clinimetric technique, the Rasch analysis, which by ordering the items in increasing difficulty, allows for the calculation of the sum of item scores to achieve a total score. Answers provide information about how FSHD affects daily and social activities and to what degree participants are able to perform usual activities. | Baseline - 3 years | |
Secondary | MIP/MEP and SNIP | For sites who routinely obtain negative inspiratory or expiratory force (MIP/MEP) will be collected. | Baseline - 3 years | |
Secondary | 4 Stair Climb | Time to ascend and descend 4 standard stairs. | Baseline - 3 years | |
Secondary | Manual Muscle Testing (MMT) | For MMT a modified Medical Research Council 13-point scale will be used - with standardized positions for each muscle. | Baseline - 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05409079 -
Schulze Muscular Dystrophy Ability Clinical Study
|
N/A | |
Recruiting |
NCT05272969 -
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
|
||
Recruiting |
NCT05902884 -
New Biomarkers in Facioscapulohumeral Muscular Dystrophy, Multispectral Optoacoustic Tomography.
|
N/A | |
Recruiting |
NCT05747924 -
Phase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD)
|
Phase 1/Phase 2 |